Username Password
S&P 500: 2,103.84
Change: -0.09%

VIROPHARMA INCORPORATED (VPHM)

Overview
Price 49.96
Price Change Today 0.00 (0.00%)
P&P rating Rating: 2
Open Price $0.00
Previous Close $49.96
Daily Range
52-Week Range $23.13 - $50.01
Volume 0
chart
Top Buy Analysis
BUY: VPHM Rating: 2
Company: VIROPHARMA INCORPORATED
Points: 151.24
Start Price: $12.87
Start Date: 12/19/2008 9:08 PM
DemonSeed
DemonSeed
P&P Score: 83.83
Recs:
Low PEG, beating estimates, estimates revised upwards, high growth rate, decreasing debt to equity and debt to capital.

This is a pharmaceutical company. The health care sector is typically not affected as much as other sectors of the economy during economic downturns.

Comments: 0 | Comment

Top Sell Analysis
SELL: VPHM Rating: 2
Company: VIROPHARMA INCORPORATED
Points: -222.14
Start Price: $12.10
Start Date: 02/25/2010 11:11 AM
harish63
harish63
P&P Score: 86.02
Recs:

Comments: 0 | Comment

Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

117 Buy
1 Sell
 
Blog Posts
User User Score Date Title Comments Last Comment
Zacks_Analysts
0.00 01/18/13 Data on ViroPharma's Cinryze - Analyst Blog 0
Zacks_Analysts
0.00 12/24/12 MDCO Scores in SOLO-1 Trial - Analyst Blog 0
Zacks_Analysts
0.00 12/24/12 MDCO Scores in SOLO-1 Trial - Analyst Blog 0
Zacks_Analysts
0.00 11/14/12 ViroPharma Presents Cinryze Data - Analyst Blog 0
Zacks_Analysts
0.00 11/14/12 ViroPharma Presents Cinryze Data - Analyst Blog 0
Zacks_Analysts
0.00 11/01/12 Watson Beats, Revises Outlook - Analyst Blog 0
Zacks_Analysts
0.00 11/01/12 Watson Beats, Revises Outlook - Analyst Blog 0
Zacks_Analysts
0.00 10/29/12 Revenues Fall at ViroPharma - Analyst Blog 0
Zacks_Analysts
0.00 10/29/12 Revenues Fall at ViroPharma - Analyst Blog 0
Zacks_Analysts
0.00 09/25/12 Pertaining to Relief for ViroPharma - Analyst Blog 0
Pages: [ 1 ]  2   3   4   5   6   7   8   9  >>
Commentary
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $6.19
Points: +552.76
Created: 02/10/2009
Outperform.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $6.19
Points: +552.27
Created: 02/10/2009
Outperform.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $6.19
Points: +552.76
Created: 02/10/2009
Outperform.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $6.19
Points: +552.27
Created: 02/10/2009
Outperform.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $6.19
Points: +552.76
Created: 02/10/2009
Outperform.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $6.19
Points: +552.27
Created: 02/10/2009
Outperform.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $12.87
Points: +151.24
Created: 12/19/2008
Low PEG, beating estimates, estimates revised upwards, high growth rate, decreasing debt to equity and debt to capital.

This is a pharmaceutical company. The health care sector is typically not affected as much as other sectors of the economy during economic downturns.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $12.87
Points: +150.77
Created: 12/19/2008
Low PEG, beating estimates, estimates revised upwards, high growth rate, decreasing debt to equity and debt to capital.

This is a pharmaceutical company. The health care sector is typically not affected as much as other sectors of the economy during economic downturns.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $12.87
Points: +151.24
Created: 12/19/2008
Low PEG, beating estimates, estimates revised upwards, high growth rate, decreasing debt to equity and debt to capital.

This is a pharmaceutical company. The health care sector is typically not affected as much as other sectors of the economy during economic downturns.

Comments: 0 | Comment

Recs:
 
BUY: VIROPHARMA INCORPORATED (VPHM) Rating: 2
Start Price: $12.87
Points: +150.77
Created: 12/19/2008
Low PEG, beating estimates, estimates revised upwards, high growth rate, decreasing debt to equity and debt to capital.

This is a pharmaceutical company. The health care sector is typically not affected as much as other sectors of the economy during economic downturns.

Comments: 0 | Comment

Recs:
 
Pages: [ 1 ]  2   3   4   5   ...  12  >>
Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
harish63 86.02 SELL Three Plus Years 02/25/2010 $12.10 $49.96
(0.00%)
+312.89% +90.75% -222.14
harish63 86.02 SELL Three Plus Years 02/25/2010 $12.10 $49.96
(0.00%)
+312.89% +91.12% -221.77
harish63 86.02 SELL Three Plus Years 02/25/2010 $12.10 $49.96
(0.00%)
+312.89% +90.75% -222.14
harish63 86.02 SELL Three Plus Years 02/25/2010 $12.10 $49.96
(0.00%)
+312.89% +91.12% -221.77
harish63 86.02 SELL Three Plus Years 02/25/2010 $12.10 $49.96
(0.00%)
+312.89% +90.75% -222.14
harish63 86.02 SELL Three Plus Years 02/25/2010 $12.10 $49.96
(0.00%)
+312.89% +91.12% -221.77
f1ndforty 47.59 BUY Six Months to a Year 04/03/2009 $5.31 $49.96
(0.00%)
+840.87% +149.71% +691.15 view
f1ndforty 47.59 BUY Six Months to a Year 04/03/2009 $5.31 $49.96
(0.00%)
+840.87% +150.20% +690.66 view
f1ndforty 47.59 BUY Six Months to a Year 04/03/2009 $5.31 $49.96
(0.00%)
+840.87% +149.71% +691.15 view
f1ndforty 47.59 BUY Six Months to a Year 04/03/2009 $5.31 $49.96
(0.00%)
+840.87% +150.20% +690.66 view
Pages: [ 1 ]  2   3   4   5   ...  12  >>
Sponsored Links